You are here:

tenofovir (Viread)

Advice

Following a full submission

tenofovir (Viread®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B in adults with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

Tenofovir has been shown to be significantly more effective than another nucleoside reverse transcriptase inhibitor in achieving a complete composite response (virological plus histological response) in a greater proportion of patients with chronic hepatitis B infection with HBeAg positive and HBeAg negative disease.

Drug Details

Drug Name: tenofovir (Viread)
SMC Drug ID: 479/08
Manufacturer: Gilead Sciences Ltd
Indication: chronic hepatitis B (CHB) in adults with compensated liver disease with evidence of active viral replication, persistently (i.e. at least 6 months) elevated serum alanine aminotra
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 July 2008

Back